Literature DB >> 20699375

Communication of BRCA results and family testing in 1,103 high-risk women.

Eleanor L Cheung1, Ashley D Olson, Tina M Yu, Pamela Z Han, Mary S Beattie.   

Abstract

BACKGROUND: Genetic testing for hereditary cancer risk has implications for individuals and families. This study of women at risk of hereditary breast and ovarian cancer examines communication of BRCA results and subsequent genetic testing in the family.
METHODS: We surveyed 1,103 female BRCA testers at two hospitals, querying for communication of results and testing in relatives.
RESULTS: Ninety-seven percent of participants communicated BRCA results with at least one relative. Communication was negatively associated with older age [odds ratio (OR), 0.66 per decade; 95% confidence interval, (95% CI), 0.4-0.9], Asian race (OR, 0.18; 95% CI, 0.06-0.5), and testing at the public hospital versus the cancer center (OR, 0.19; 95% CI, 0.07-0.5). Communication was positively associated with increased knowledge of hereditary breast and ovarian cancer screening and risk reduction recommendations (OR, 1.9; 95% CI, 1.1-3.4) and increased satisfaction with the decision to BRCA test (OR, 2.6; 95% CI, 1.6-4.0). Seventy-five percent of BRCA-positive participants reported that at least one relative pursued genetic testing. Family testing was negatively associated with Asian race (OR, 0.15; 95% CI, 0.02-0.8) and positively associated with increased socioeconomic status (OR, 1.4; 95% CI, 1.1-1.7) and increased satisfaction with decision (OR, 2.1; 95% CI, 1.1-4.1).
CONCLUSION: Despite high overall rates of communicating BRCA results, underserved and some minority women seem less likely to inform relatives of their BRCA status or have relatives test for a known family mutation. Satisfaction with the decision to BRCA test is positively associated with both outcomes. IMPACT: This study identified several novel predictors of family communication and family genetic testing in a large population of high-risk women. This work can inform clinicians interested in improving family communication regarding cancer predisposition testing. (c)2010 AACR.

Entities:  

Mesh:

Year:  2010        PMID: 20699375      PMCID: PMC3207738          DOI: 10.1158/1055-9965.EPI-10-0325

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  25 in total

1.  Family communication about positive BRCA1 and BRCA2 genetic test results.

Authors:  Bobbi McGivern; Jessica Everett; Geoffrey G Yager; Robert C Baumiller; Amanda Hafertepen; Howard M Saal
Journal:  Genet Med       Date:  2004 Nov-Dec       Impact factor: 8.822

Review 2.  Influence of race/ethnicity on genetic counseling and testing for hereditary breast and ovarian cancer.

Authors:  Andrea D Forman; Michael J Hall
Journal:  Breast J       Date:  2009 Sep-Oct       Impact factor: 2.431

3.  Communication with close and distant relatives in the context of genetic testing for hereditary breast and ovarian cancer in cancer patients.

Authors:  Erna Claes; Gerry Evers-Kiebooms; Andrea Boogaerts; Marleen Decruyenaere; Lieve Denayer; Eric Legius
Journal:  Am J Med Genet A       Date:  2003-01-01       Impact factor: 2.802

4.  Patient satisfaction with health care decisions: the satisfaction with decision scale.

Authors:  M Holmes-Rovner; J Kroll; N Schmitt; D R Rovner; M L Breer; M L Rothert; G Padonu; G Talarczyk
Journal:  Med Decis Making       Date:  1996 Jan-Mar       Impact factor: 2.583

5.  Communication of BRCA1 and BRCA2 results to at-risk relatives: a cancer risk assessment program's experience.

Authors:  Josephine Wagner Costalas; Mark Itzen; John Malick; James S Babb; Betsy Bove; Andrew K Godwin; Mary B Daly
Journal:  Am J Med Genet C Semin Med Genet       Date:  2003-05-15       Impact factor: 3.908

6.  The "duty to warn" a patient's family members about hereditary disease risks.

Authors:  Kenneth Offit; Elizabeth Groeger; Sam Turner; Eve A Wadsworth; Mary A Weiser
Journal:  JAMA       Date:  2004-09-22       Impact factor: 56.272

7.  Attitudes about genetic testing for breast-ovarian cancer susceptibility.

Authors:  C Lerman; M Daly; A Masny; A Balshem
Journal:  J Clin Oncol       Date:  1994-04       Impact factor: 44.544

8.  Effect of a computer-based decision aid on knowledge, perceptions, and intentions about genetic testing for breast cancer susceptibility: a randomized controlled trial.

Authors:  Michael J Green; Susan K Peterson; Maria Wagner Baker; Gregory R Harper; Lois C Friedman; Wendy S Rubinstein; David T Mauger
Journal:  JAMA       Date:  2004-07-28       Impact factor: 56.272

9.  Psychological side effects of breast cancer screening.

Authors:  C Lerman; B Trock; B K Rimer; C Jepson; D Brody; A Boyce
Journal:  Health Psychol       Date:  1991       Impact factor: 4.267

10.  Breast cancer risk counseling improves women's functioning.

Authors:  Deborah J Bowen; Wylie Burke; Anne McTiernan; Yutaka Yasui; M Robyn Andersen
Journal:  Patient Educ Couns       Date:  2004-04
View more
  36 in total

Review 1.  Specific psychosocial issues of individuals undergoing genetic counseling for cancer - a literature review.

Authors:  Willem Eijzenga; Daniela E E Hahn; Neil K Aaronson; Irma Kluijt; Eveline M A Bleiker
Journal:  J Genet Couns       Date:  2013-08-31       Impact factor: 2.537

2.  "Second-Class Status?" Insight into Communication Patterns and Common Concerns Among Men with Hereditary Breast and Ovarian Cancer Syndrome.

Authors:  Alexandra Suttman; Robert Pilarski; Doreen M Agnese; Leigha Senter
Journal:  J Genet Couns       Date:  2018-02-05       Impact factor: 2.537

3.  The uptake of presymptomatic genetic testing in hereditary breast-ovarian cancer and Lynch syndrome: a systematic review of the literature and implications for clinical practice.

Authors:  Fred H Menko; Jacqueline A Ter Stege; Lizet E van der Kolk; Kiki N Jeanson; Winnie Schats; Daoud Ait Moha; Eveline M A Bleiker
Journal:  Fam Cancer       Date:  2019-01       Impact factor: 2.375

4.  Update on multi-gene panel testing and communication of genetic test results.

Authors:  Sonya Reid; Tuya Pal
Journal:  Breast J       Date:  2020-07-08       Impact factor: 2.431

Review 5.  Disparities in gynecologic cancer genetics evaluation.

Authors:  Emily M Hinchcliff; Erica M Bednar; Karen H Lu; J Alejandro Rauh-Hain
Journal:  Gynecol Oncol       Date:  2019-01-31       Impact factor: 5.482

6.  Genetic Diagnosis before Surgery has an Impact on Surgical Decision in BRCA Mutation Carriers with Breast Cancer.

Authors:  Sungmin Park; Jeong Eon Lee; Jai Min Ryu; Issac Kim; Soo Youn Bae; Se Kyung Lee; Jonghan Yu; Seok Won Kim; Seok Jin Nam
Journal:  World J Surg       Date:  2018-05       Impact factor: 3.352

Review 7.  Communication and technology in genetic counseling for familial cancer.

Authors:  H T Lynch; C Snyder; M Stacey; B Olson; S K Peterson; S Buxbaum; T Shaw; P M Lynch
Journal:  Clin Genet       Date:  2013-12-20       Impact factor: 4.438

8.  The big reveal: Family disclosure patterns of BRCA genetic test results among young Black women with invasive breast cancer.

Authors:  Claire C Conley; Dana Ketcher; Maija Reblin; Monica L Kasting; Deborah Cragun; Jongphil Kim; Kimlin Tam Ashing; Cheryl L Knott; Chanita Hughes-Halbert; Tuya Pal; Susan T Vadaparampil
Journal:  J Genet Couns       Date:  2020-01-07       Impact factor: 2.537

9.  Preparing individuals to communicate genetic test results to their relatives: report of a randomized control trial.

Authors:  Susan V Montgomery; Andrea M Barsevick; Brian L Egleston; Ruth Bingler; Karen Ruth; Suzanne M Miller; John Malick; Terrence P Cescon; Mary B Daly
Journal:  Fam Cancer       Date:  2013-09       Impact factor: 2.375

10.  Communicating with Daughters About Familial Risk of Breast Cancer: Individual, Family, and Provider Influences on Women's Knowledge of Cancer Risk.

Authors:  Lucy A Peipins; Juan L Rodriguez; Nikki A Hawkins; Ashwini Soman; Mary C White; M Elizabeth Hodgson; Lisa A DeRoo; Dale P Sandler
Journal:  J Womens Health (Larchmt)       Date:  2018-01-29       Impact factor: 2.681

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.